tbuckley/cabot-search huggingface dataset:
Особливості лікування метаболічних змін при цукровому діабеті 2 типу, ожирінні та артеріальній гіпертензії в пацієнтів з остеоартрозом з урахуванням генотипів гена протизапального інтерлейкіну-10 (IL-10, C592A)
Authors: J.I. Serdulets
Journal: GASTROENTEROLOGY (2018)

Актуальність. Низка досліджень вказує на причетність хронічного системного запалення до патогенезу та прогресування метаболічного синдрому (цукровий діабет 2 типу з ожирінням та артеріальною гіпертензією) з остеоартрозом. Його інтенсифікація за такої поліморбідності призводить до порушення мікроциркуляції, структури колагену і сприяє прогресуванню дегенеративного процесу в суглобових тканинах, де певну роль відіграє білок позаклітинного матриксу матрилін-3. Доведено, що він асоціюється з рівнем відповідних генотипів прозапальних і протизапальних генів. Метою дослідження було вивчити зміни показників генотипів гена протизапального інтерлейкіну-10 (IL-10, C592A) під впливом лікування у хворих на остеоартроз за поєднання з цукровим діабетом 2 типу, ожирінням, артеріальною гіпертензією. Матеріали та методи. Обстежені 116 пацієнтів із цукровим діабетом 2 типу, ожирінням та артеріальною гіпертензією, віком від 16 до 65 років (середній вік — 40,5 року). Для аналізу ефективності лікування залежно від генотипів гена протизапального інтерлейкіну-10 проводили поділ обстежених на групи з урахуванням цих генотипів. Результати. Установлено, що використання запропонованого способу лікування сприяло зменшенню больових відчуттів на 70,6 %, поліпшило рухливість у суглобах, зменшило показник індексу НОМА більше ніж у 20 % хворих у ІІІ групі. Артеріальний тиск суттєво не змінювався. Завдяки лікуванню вірогідно знижувалась активність пероксидації ліпідів (ефективніше у носіїв С-алелі гена IL-10 (C592A)) та тлі невірогідного зростання протиоксидантного захисту, що не мало залежності від поліморфних варіантів гена IL-10 (rs1800872). Концентрація прозапального цитокіна ІL-18 зменшувалась у носіїв СС-генотипу на 25,6 %, СА-генотипу — на 18,58 %, АА-генотипу — на 15,37 % (р &gt; 0,05). А вміст протизапального ІL-10, навпаки, зростав — на 11,69, 18,0 та 23,08 % (р &gt; 0,05) відповідно. Установлено незначне підвищення позаклітинного матриксного білка матриліну-3 в носіїв СС-генотипу на 4,4 %, СА-генотипу — на 13,5 % та АА-генотипу гена IL-10 (C592A) — на 13,8 % (р &gt; 0,05). Висновки. Установлено вірогідне зниження активності показників пероксидації ліпідів (ефективніше в носіїв С-алелі гена IL-10 (C592A)) та тлі невірогідного зростання протиоксидантного захисту, що не залежало від поліморфних варіантів гена IL-10 (rs1800872). Під впливом терапії концентрація ІL-18 зменшувалась у носіїв СС-генотипу та СА-генотипу, а вміст ІL-10, навпаки, зростав у носіїв АА-генотипу гена IL-10 (C592A). Саме у цих хворих поліпшувалися показники матриліну-3. Подальше дослідження буде стосуватися вивчення впливу запропонованого способу лікування на стан протеолітичної та колагенолітичної активності в пацієнтів із метаболічним синдромом та остеоартрозом.
CKD273 Enables Efficient Prediction of Diabetic Nephropathy in Nonalbuminuric Patients
Authors: Petra Zürbig, Harald Mischak, Jan Menne, Hermann Haller
Journal: Diabetes Care (2018)

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease in developed nations. Significant albuminuria has long been regarded as the hallmark of DN. Despite this clearly defined indicator, a significant fraction of patients with diabetes develop renal impairment without significant albuminuria, with a variable percentage of patients having advanced kidney disease (1). This observation has resulted in the hypothesis of two distinct pathways (Alb+ and Alb−) of progression toward DN, as suggested by different sets of covariates associated with the two phenotypes. Based on data from the National Health and Nutrition Examination Surveys (NHANES), the number of adults with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 and absence of albuminuria increased during the last 30 years (2). Furthermore, mortality rates increased in those with an eGFR <60 mL/min/1.73 m2 without albuminuria from 35 to 51 deaths per 1,000 person-years during this time. Improved strategies are required for the management of patients developing DN without albuminuria. Biomarkers are urgently needed to identify the nonalbuminuric patients at early stages of DN.

CKD273 is a multidimensional urinary proteome classifier consisting of 273 protein fragments, predicting deterioration of renal function (3 …
Efficacy and tolerability of olaparib in Asian patients with recurrent ovarian, primary peritoneal or fallopian tube carcinoma: The National University Cancer Institute, Singapore experience
Authors: V.Y.M. Heong, Y.W. Lim, S.C. Lee, S. Ow, S.E. Lim, P.Y. Ong, J. Low, J. Ng, A. Ilancheran, P. Tong, D. Lim, D. Tan
Journal: Annals of Oncology (2018)
Abstract 20775: Perceived Control Independently Predicts Frequency, Severity and Burden From Heart Failure Symptoms
Authors: Chin-Yen Lin, Debra K Moser, Terry A Lennie
Journal: Circulation (2017)

Introduction: Heart failure (HF) is a symptom-driven condition. As such it is important to understand factors that are associated with symptom status, particularly factors that are amenable to chan...
Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor—Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
Authors: Qian Jiang, Xiao Jun Huang, Zi Chen, Lichuang Men, Wei Liu, Xuemei Sun, Jiao JI, Hengbang Wang, Yue Hou, Po Hu, Lei Zou, Hua Yan, Yingjie Huang, Dajun Yang, Yifan Zhai
Journal: Blood (2018)
Rejuvenation of β cells by epigenetic editing
Authors: Tao Wang, Duanqing Pei
Journal: Journal of Clinical Investigation (2018)

Insulin-secreting β cell loss or dysfunction is a feature of both type 1 and type 2 diabetes. Strategies to restore β cell mass are limited, as sources of healthy islets are scarce and mature β cells are not readily expanded in vitro. In this issue of the JCI, Ou et al. report that mature β cell expansion can be induced in situ through epigenetic editing of regulatory elements in pancreatic tissue. Specifically, hypomethylation at imprinting control region 2 (ICR2) in human islets promoted β cell expansion. Importantly, transplantation of these epigenetically edited islets into diabetic mice reduced blood glucose levels. Together, these results support further evaluation of this strategy for restoring β cell mass in patients with diabetes.
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK
Authors: Roger Williams, Graeme Alexander, Richard Aspinall, Rachel Batterham, Neeraj Bhala, Nick Bosanquet, Katherine Severi, Anya Burton, Robyn Burton, Matthew E Cramp, Natalie Day, Anil Dhawan, John Dillon, Colin Drummond, Jessica Dyson, James Ferguson, Graham R Foster, Ian Gilmore, Jonny Greenberg, Clive Henn, Mark Hudson, Helen Jarvis, Deirdre Kelly, Jake Mann, Neil McDougall, Martin McKee, Kieran Moriarty, Joanne Morling, Philip Newsome, John O'Grady, Liz Rolfe, Peter Rice, Harry Rutter, Nick Sheron, Douglas Thorburn, Julia Verne, Jyotsna Vohra, John Wass, Andrew Yeoman
Journal: The Lancet (2018)
Obesity in pregnancy needs specialist multidisciplinary care, says royal college
Authors: Zosia Kmietowicz
Journal: BMJ (2018)

Women who are obese should be supported to lose weight before conception and between pregnancies to ensure the healthiest possible outcome for mother and baby, says new clinical guidance from the Royal College of Obstetricians and Gynaecologists.1

Fiona Denison, chair of translational obstetrics at the University of Edinburgh and lead author of the guideline, said, “Pregnancy provides an opportunity for healthcare professionals to connect with women at a time when they are generally more concerned about their health. By making healthy changes to their diet and exercise, women who are obese may limit the amount of extra weight they gain during pregnancy.

“Losing …
Silicate-based bioceramic scaffolds for dual-lineage regeneration of osteochondral defect
Authors: Varitsara Bunpetch, Xiaoan Zhang, Tian Li, Junxin Lin, Ewetse Paul Maswikiti, Yan Wu, Dandan Cai, Jun Li, Shufang Zhang, Chengtie Wu, Hongwei Ouyang
Journal: Biomaterials (2018)
Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals
Authors: Valérie E.H. Pittet, Michel H. Maillard, Thomas Simonson, Nicolas Fournier, Gerhard Rogler, Pierre Michetti, Claudia Anderegg, Peter Bauerfeind, Christoph Beglinger, Stefan Begré, Dominique Belli, José M. Bengoa, Luc Biedermann, Beat Bigler, Janek Binek, Mirjam Blattmann, Stephan Boehm, Jan Borovicka, Christian P. Braegger, Nora Brunner, Patrick Bühr, Bernard Burnand, Emanuel Burri, Sophie Buyse, Matthias Cremer, Dominique H. Criblez, Philippe de Saussure, Lukas Degen, Joakim Delarive, Christopher Doerig, Barbara Dora, Gian Dorta, Mara Egger, Tobias Ehmann, Ali El-Wafa, Matthias Engelmann, Jessica Ezri, Christian Felley, Markus Fliegner, Nicolas Fournier, Montserrat Fraga, Pascal Frei, Remus Frei, Michael Fried, Florian Froehlich, Christian Funk, Raoul Ivano Furlano, Suzanne Gallot-Lavallée, Martin Geyer, Marc Girardin, Delphine Golay, Tanja Grandinetti, Beat Gysi, Horst Haack, Johannes Haarer, Beat Helbling, Peter Hengstler, Denise Herzog, Cyrill Hess, Klaas Heyland, Thomas Hinterleitner, Philippe Hiroz, Claudia Hirschi, Petr Hruz, Rika Iwata, Res Jost, Pascal Juillerat, Céline Keller, Christina Knellwolf, Christoph Knoblauch, Henrik Köhler, Rebekka Koller, Claudia Krieger-Grübel, Gerd Kullak-Ublick, Patrizia Künzler, Markus Landolt, Rupprecht Lange, Frank Serge Lehmann, Andrew Macpherson, Philippe Maerten, Michel H. Maillard, Christine Manser, Michael Manz, Urs Marbet, George Marx, Christoph Matter, Rémy Meier, Martina Mendanova, Pierre Michetti, Benjamin Misselwitz, Bernhard Morell, Patrick Mosler, Christian Mottet, Christoph Müller, Pascal Müller, Beat Müllhaupt, Claudia Münger-Beyeler, Leilla Musso, Andreas Nagy, Michaela Neagu, Cristina Nichita, Jan Niess, Andreas Nydegger, Nicole Obialo, Carl Oneta, Cassandra Oropesa, Ueli Peter, Daniel Peternac, Laetitia Marie Petit, Franziska Piccoli-Gfeller, Julia Beatrice Pilz, Valérie Pittet, Nadia Raschle, Ronald Rentsch, Sophie Restellini, Jean-Pierre Richterich, Sylvia Rihs, Marc Alain Ritz, Jocelyn Roduit, Daniela Rogler, Gerhard Rogler, Jean-Benoît Rossel, Vanessa Rueger, Gaby Saner, Bernhard Sauter, Mikael Sawatzki, Michela Schäppi, Michael Scharl, Sylvie Scharl, Martin Schelling, Susanne Schibli, Hugo Schlauri, Sybille Schmid Uebelhart, Jean-François Schnegg, Alain Schoepfer, Frank Seibold, Mariam Seirafi, Gian-Marco Semadeni, David Semela, Arne Senning, Marc Sidler, Christiane Sokollik, Johannes Spalinger, Holger Spangenberger, Philippe Stadler, Michael Steuerwald, Alex Straumann, Bigna Straumann-Funk, Michael Sulz, Alexandra Suter, Joël Thorens, Sarah Tiedemann, Radu Tutuian, Stephan Vavricka, Francesco Viani, Jürg Vögtlin, Roland Von Känel, Alain Vonlaufen, Dominique Vouillamoz, Rachel Vulliamy, Jürg Wermuth, Helene Werner, Paul Wiesel, Reiner Wiest, Tina Wylie, Jonas Zeitz, Dorothee Zimmermann
Journal: Clinical Gastroenterology and Hepatology (2018)
Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα
Authors: Min Yan, Huan Qi, Tian Xia, Xinjie Zhao, Wen Wang, Zhichao Wang, Chang Lu, Zhen Ning, Huan Chen, Tongming Li, Dinesh Singh Tekcham, Xiumei Liu, Jing Liu, Di Chen, Xiaolong Liu, Guowang Xu, Hai-long Piao
Journal: Metabolism (2018)
Medical cannabis in the UK
Authors: Alex Stevens
Journal: BMJ (2018)

Patients should not be criminalised for seeking benefits:
Do patients have the right to medicate themselves, or should they be punished for doing so? Should their doctors work with them to decide on the best treatment, or does the government know best? These questions are at the heart of the current debate on the use of cannabis as medicine.

In the UK, “cannabis based products for medical use in humans” were rescheduled on 1 November 2018. They were placed in schedule 2 of the Misuse of Drugs Regulations, alongside several opioid analgesics. In theory, this means they can now be prescribed. In practice, the NHS has warned that “very few people in England are likely to get a prescription for medical cannabis,” because of the tight restrictions that have been put in place....
Comparison of suture button fixation and syndesmotic screw fixation in the treatment of distal tibiofibular syndesmosis injury: A systematic review and meta-analysis
Authors: Linzhen Xie, Huanguang Xie, Jinwu Wang, Chunhui Chen, Chuanxu Zhang, Hua Chen, Wenhao Zheng
Journal: International Journal of Surgery (2018)
Vulvar Paget disease: A national retrospective cohort study
Authors: Michelle van der Linden, Maaike H.M. Oonk, Helena C. van Doorn, Johan Bulten, Eleonora B.L. van Dorst, Guus Fons, Christianne A.R. Lok, Mariëtte I.E. van Poelgeest, Brigitte M.F. Slangen, Leon F.A.G. Massuger, Joanne A. de Hullu
Journal: Journal of the American Academy of Dermatology (2018)
Improvement in Outcomes After Cardiac Arrest and Resuscitation by Inhibition of S-Nitrosoglutathione Reductase
Authors: Kei Hayashida, Aranya Bagchi, Yusuke Miyazaki, Shuichi Hirai, Divya Seth, Michael G. Silverman, Emanuele Rezoagli, Eizo Marutani, Naohiro Mori, Aurora Magliocca, Xiaowen Liu, Lorenzo Berra, Allyson G. Hindle, Michael W. Donnino, Rajeev Malhotra, Matthews O. Bradley, Jonathan S. Stamler, Fumito Ichinose
Journal: Circulation (2019)

Background: The biological effects of nitric oxide are mediated via protein S-nitrosylation. Levels of S-nitrosylated protein are controlled in part by the denitrosylase, S-nitrosoglutathione reductase (GSNOR). The objective of this study was to examine whether GSNOR inhibition improves outcomes after cardiac arrest and cardiopulmonary resuscitation (CA/CPR). Methods: Adult wild-type C57BL/6 and GSNOR-deleted (GSNOR −/− ) mice were subjected to potassium chloride-induced CA and subsequently resuscitated. Fifteen minutes after a return of spontaneous circulation, wild-type mice were randomized to receive the GSNOR inhibitor, SPL-334.1, or normal saline as placebo. Mortality, neurological outcome, GSNOR activity, and levels of S-nitrosylated proteins were evaluated. Plasma GSNOR activity was measured in plasma samples obtained from post-CA patients, preoperative cardiac surgery patients, and healthy volunteers. Results: GSNOR activity was increased in plasma and multiple organs of mice, including brain in particular. Levels of protein S-nitrosylation were decreased in the brain 6 hours after CA/CPR. Administration of SPL-334.1 attenuated the increase in GSNOR activity in brain, heart, liver, spleen, and plasma, and restored S-nitrosylated protein levels in the brain. Inhibition of GSNOR attenuated ischemic brain injury and improved survival in wild-type mice after CA/CPR (81.8% in SPL-334.1 versus 36.4% in placebo; log rank P =0.031). Similarly, GSNOR deletion prevented the reduction in the number of S-nitrosylated proteins in the brain, mitigated brain injury, and improved neurological recovery and survival after CA/CPR. Both GSNOR inhibition and deletion attenuated CA/CPR-induced disruption of blood brain barrier. Post-CA patients had higher plasma GSNOR activity than did preoperative cardiac surgery patients or healthy volunteers ( P &lt;0.0001). Plasma GSNOR activity was positively correlated with initial lactate levels in postarrest patients (Spearman correlation coefficient=0.48; P =0.045). Conclusions: CA and CPR activated GSNOR and reduced the number of S-nitrosylated proteins in the brain. Pharmacological inhibition or genetic deletion of GSNOR prevented ischemic brain injury and improved survival rates by restoring S-nitrosylated protein levels in the brain after CA/CPR in mice. Our observations suggest that GSNOR is a novel biomarker of postarrest brain injury as well as a molecular target to improve outcomes after CA.
AB0407 The impact of depression on social contacts of patients with reumatoid arthritis
Authors: T. Jankovic, J. Zvekic Svorcan
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) affects the psychological and emotional state of the patient, leading to a significant reduction in the quality of life and social contacts. <h3>Objectives</h3> Assess the occurrence and degree of depression in RA patients and their impact on quality of life and social contacts. <h3>Methods</h3> The study involved 110 patients, 78.4% women and 22.6% men, with RA of median age 58.7. The average disease duration was 13.6 years. 68% of patients were treated with methotrexate monotherapy (MTX), 32% by combination of MTX and other DMARD. The disease activity in patients was determined by the ideax DAS28, the functional status -HAQ-DI questionnaire. The intensity of the pain was determined using a visual analogue scale for VAS pain (0–100 mm). The degree of radiological changes was determined based on the classification by Steinbrocker. Patients completed a questionnaire related to the quality of social relationships. The degree of depression was determined using Bäck scale for depression. <h3>Results</h3> The incidence of depression had 65.4% of the patients. A mild degree of depression was observed in 26.4%, moderate 24%, expressed 13% while 2% of the patients had a more severe degree. There was a significant statistic correlation between the degree of depression with age, the duration of the disease, the high degree of DAS28, HAQ-DI, VAS pain and the degree of radiological changes. By analysing the quality of life and social contact, patients in 62% were supported by a close family and a spouse, 28% of their close relatives, 7% of the wider family, while 3% of the patients lived alone. <h3>Conclusions</h3> Depression is the most common and most important psychological state that occurs in patients with RA. It is important to recognise and start treatment on time, which should be based on a multidisciplinary approach. In addition to family support, overall social support also takes a significant place. <h3>Disclosure of Interest</h3> None declared
Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer
Authors: Kunal Nagpal, Davis Foote, Yun Liu, Po-Hsuan Cameron Chen, Ellery Wulczyn, Fraser Tan, Niels Olson, Jenny L. Smith, Arash Mohtashamian, James H. Wren, Greg S. Corrado, Robert MacDonald, Lily H. Peng, Mahul B. Amin, Andrew J. Evans, Ankur R. Sangoi, Craig H. Mermel, Jason D. Hipp, Martin C. Stumpe
Journal: npj Digital Medicine (2019)

For prostate cancer patients, the Gleason score is one of the most important prognostic factors, potentially determining treatment independent of the stage. However, Gleason scoring is based on subjective microscopic examination of tumor morphology and suffers from poor reproducibility. Here we present a deep learning system (DLS) for Gleason scoring whole-slide images of prostatectomies. Our system was developed using 112 million pathologist-annotated image patches from 1226 slides, and evaluated on an independent validation dataset of 331 slides. Compared to a reference standard provided by genitourinary pathology experts, the mean accuracy among 29 general pathologists was 0.61 on the validation set. The DLS achieved a significantly higher diagnostic accuracy of 0.70 (p = 0.002) and trended towards better patient risk stratification in correlations to clinical follow-up data. Our approach could improve the accuracy of Gleason scoring and subsequent therapy decisions, particularly where specialist expertise is unavailable. The DLS also goes beyond the current Gleason system to more finely characterize and quantitate tumor morphology, providing opportunities for refinement of the Gleason system itself.
The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Authors: Alexander Röth, Miklos Egyed, Satochi Ichikawa, Jin Seok Kim, Zsolt Nagy, Julia Gaàl Weisinger, Jens P. Panse, Regis Peffault De Latour, Flore Sicre De Fontbrune, Simona Sica, Kensuke Usuki, Sung-Soo Yoon, Erica Winter, Joy C. Hsu, Andreas Dieckmann, Judith Anzures-Cabrera, Gregor Jordan, Kenji Shinomiya, Barbara Klughammer, Christoph Bucher, Angelika Jahreis, Jun-Ichi Nishimura
Journal: Blood (2018)
Gender differences in risk of developing nasopharyngeal cancer (NPC) in one of the highest NPC ethnic in the world
Authors: C.K. Tan, S.P. Beh, R.-Y. Lee, V. Pei Jye, S. Damoderam, N.I. Mohd Naseri, U. Nagaswara, G.G. Yeo
Journal: Annals of Oncology (2018)
Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial
Authors: Samir R. Kapadia, Chetan P. Huded, Susheel K. Kodali, Lars G. Svensson, E. Murat Tuzcu, Suzanne J. Baron, David J. Cohen, D. Craig Miller, Vinod H. Thourani, Howard C. Herrmann, Michael J. Mack, Molly Szerlip, Raj R. Makkar, John G. Webb, Craig R. Smith, Jeevanantham Rajeswaran, Eugene H. Blackstone, Martin B. Leon
Journal: Journal of the American College of Cardiology (2018)
Have Tent, Will Do Pop-up HIV Screening
Authors: Rita Rubin
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Noise pollution in hospitals
Authors: Andreas Xyrichis, John Wynne, Jamie Mackrill, Anne Marie Rafferty, Angus Carlyle
Journal: BMJ (2018)

Noise in hospitals is a common grievance among patients, families, and staff.1 In the US, “quietness of hospital environment” is among the lowest scoring items on patient surveys.2 In the UK, 40% of hospital patients are bothered by noise at night, a consistent finding of the NHS Inpatient Survey.1 Hospital noise is a steadily worsening problem, with levels regularly exceeding international recommendations.3 4 Noise levels over 100 dB have been measured in intensive care units,4 the equivalent of loud music through headphones and the point beyond which damage to hair cells in the ear can occur. 

This is an article published in the British Medical Journal (BMJ) based on an interdisciplinary project entitled HPNoSS, Hospital Project on Noise and Sleep in Hospitals.
Dynamic Hydrogels: Dynamic PEG–Peptide Hydrogels via Visible Light and FMN‐Induced Tyrosine Dimerization (Adv. Healthcare Mater. 22/2018)
Authors: Hung‐Yi Liu, Han D. Nguyen, Chien‐Chi Lin
Journal: Advanced Healthcare Materials (2018)

In article 1800954 by Chien-Chi Lin and co-workers, a dynamic hydrogel system is prepared using orthogonal photochemistry. The primary network is crosslinked by modular thiol-norbornene photoclick reaction, whereas the secondary stiffening is achieved via visible light-induced di-tyrosine crosslinking. All components used are commercially available, making the system highly adaptable for studying the effect of spatial-temporally regulated matrix mechanics on cell fate processes.